<PAGE>
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
 
                                 UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549
 
                            ------------------------
 
                                   FORM 10-Q
 
(MARK ONE)
 
/X/ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
                                  ACT OF 1934
 
                  FOR THE QUARTERLY PERIOD ENDED JUNE 30, 1997
 
                                       OR
 
/ / TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
                                  ACT OF 1934
 
         FOR THE TRANSITION PERIOD FROM            TO
 
                         COMMISSION FILE NUMBER 0-28328
 
                            ------------------------
 
                                  UROCOR, INC.
 
             (Exact name of registrant as specified in its charter)
 
<TABLE>
<S>                                       <C>
               DELAWARE                                 75-2117882
       (State of incorporation)             (IRS Employer Identification No.)
 
 800 RESEARCH PARKWAY, OKLAHOMA CITY,                     73104
                  OK
   (Address of principal executive                      (zip code)
               offices)
</TABLE>
 
                                 (405) 290-4000
 
              (Registrant's telephone number, including area code)
 
                                 NOT APPLICABLE
 
   (Former name, former address and former fiscal year, if changed since last
                                    report)
 
                            ------------------------
 
    Indicate by check mark whether the registrant: (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports) and (2) has been subject to such
filing requirements for the past 90 days. Yes /X/  No / /
 
    The number of shares of issuer's Common Stock, $.01 par value, outstanding
on July 31, 1997 was 10,176,439 shares.
 
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
<PAGE>
                                  UROCOR, INC.
                                   FORM 10-Q
                      FOR THE QUARTER ENDED JUNE 30, 1997
                                     INDEX
                         PART I--FINANCIAL INFORMATION
 
<TABLE>
<CAPTION>
                                                                                                              PAGE
                                                                                                            ---------
<S>           <C>                                                                                           <C>
ITEM 1.       FINANCIAL STATEMENTS (UNAUDITED)
 
              Balance Sheets as of June 30, 1997 and December 31, 1996....................................      3
 
              Statements of Operations for the three months and six months ended June 30, 1997 and 1996...      4
 
              Statements of Cash Flows for the six months ended June 30, 1997 and 1996....................      5
 
              Notes to Unaudited Interim Financial Statements--June 30, 1997..............................      6
 
ITEM 2.       MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.......     7-9
 
ITEM 3.       QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS.................................      9
 
                                             PART II--OTHER INFORMATION
 
ITEM 1.       LEGAL PROCEEDINGS
 
ITEM 2.       CHANGES IN SECURITIES
 
ITEM 3.       DEFAULTS UPON SENIOR SECURITIES
 
ITEM 4.       SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
 
ITEM 5.       OTHER INFORMATION
              Cautionary Statements.......................................................................    10-13
 
ITEM 6.       EXHIBITS AND REPORTS ON FORM 8-K............................................................     13
 
Signatures................................................................................................     14
</TABLE>
 
                                       2
<PAGE>
                         PART I--FINANCIAL INFORMATION
 
ITEM 1.  FINANCIAL STATEMENTS
 
                                  UROCOR, INC.
                                 BALANCE SHEETS
 
<TABLE>
<CAPTION>
                                                                                                    DECEMBER 31,
                                                                                                        1996
                                                                                       JUNE 30,     -------------
                                                                                         1997
                                                                                     -------------
                                                                                      (UNAUDITED)
<S>                                                                                  <C>            <C>
                                                     ASSETS
CURRENT ASSETS:
  Cash and cash equivalents........................................................  $  10,642,034  $  15,796,070
  Short-term marketable investments................................................      2,998,913      5,975,500
  Accounts receivable, net of allowance for doubtful accounts of $1,717,425 in 1997
    and $1,123,562 in 1996.........................................................     12,555,825      8,188,715
  Prepaid expenses.................................................................        948,969        666,662
  Laboratory supplies, at average cost.............................................        496,118        683,408
  Other current assets.............................................................      1,093,154        530,796
                                                                                     -------------  -------------
    Total current assets...........................................................     28,735,013     31,841,151
                                                                                     -------------  -------------
LONG-TERM MARKETABLE INVESTMENTS...................................................     12,705,059     11,703,521
PROPERTY AND EQUIPMENT, net........................................................      6,890,307      4,745,662
INTANGIBLE AND OTHER ASSETS, net...................................................      2,083,268      1,979,575
                                                                                     -------------  -------------
    Total assets...................................................................  $  50,413,647  $  50,269,909
                                                                                     -------------  -------------
                                                                                     -------------  -------------
 
                                      LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
  Accounts payable.................................................................  $   1,091,308  $   1,960,446
  Accrued compensation.............................................................        546,324      1,225,976
  Other accrued liabilities........................................................        149,539        114,352
  Current installments of obligations under capital leases.........................        571,650        623,446
                                                                                     -------------  -------------
    Total current liabilities......................................................      2,358,821      3,924,220
LINE OF CREDIT, long-term..........................................................       --             --
OBLIGATIONS UNDER CAPITAL LEASES, net of current installments......................        392,165        659,131
                                                                                     -------------  -------------
    Total liabilities..............................................................      2,750,986      4,583,351
                                                                                     -------------  -------------
STOCKHOLDERS' EQUITY:
  Convertible preferred stock, $.01 par value--authorized 6,000,000 shares at June
    30, 1997 and at December 31, 1996; issued in series; no shares outstanding at
    June 30, 1997 and at December 31, 1996.........................................       --             --
  Common stock, $.01 par value, authorized 20,000,000 shares at June 30, 1997 and
    at December 31, 1996; 10,171,089 shares issued and outstanding at June 30, 1997
    and 10,101,307 shares issued and outstanding at December 31, 1996..............        101,711        101,013
  Additional paid-in capital.......................................................     57,710,705     57,576,724
  Accumulated deficit..............................................................    (10,149,755)   (11,991,179)
                                                                                     -------------  -------------
    Total stockholders' equity.....................................................     47,662,661     45,686,558
                                                                                     -------------  -------------
    Total liabilities and stockholders' equity.....................................  $  50,413,647  $  50,269,909
                                                                                     -------------  -------------
                                                                                     -------------  -------------
</TABLE>
 
      The accompanying notes are an integral part of these balance sheets.
 
                                       3
<PAGE>
                                  UROCOR, INC.
                            STATEMENTS OF OPERATIONS
                                  (UNAUDITED)
 
<TABLE>
<CAPTION>
                                                      THREE MONTHS ENDED JUNE 30,    SIX MONTHS ENDED JUNE 30,
                                                      ----------------------------  ----------------------------
                                                          1997           1996           1997           1996
                                                      -------------  -------------  -------------  -------------
<S>                                                   <C>            <C>            <C>            <C>
REVENUE.............................................  $   7,794,707  $   6,449,173  $  15,873,272  $  12,356,722
 
OPERATING EXPENSES:
  Direct cost of services and products..............      2,923,834      2,390,159      5,904,936      4,528,202
  Selling, general and administrative expenses......      3,990,749      3,103,859      7,680,110      5,965,736
  Research and development..........................        611,403        648,540      1,221,456      1,292,312
                                                      -------------  -------------  -------------  -------------
    Total operating expenses........................      7,525,986      6,142,558     14,806,502     11,786,250
                                                      -------------  -------------  -------------  -------------
  Income from operations............................        268,721        306,615      1,066,770        570,472
 
OTHER INCOME (EXPENSE):
  Interest income...................................        413,957        214,063        867,574        237,351
  Interest expense..................................        (42,350)       (53,383)       (92,930)      (109,889)
                                                      -------------  -------------  -------------  -------------
    Total other income..............................        371,607        160,680        774,644        127,462
                                                      -------------  -------------  -------------  -------------
Income before income taxes..........................        640,328        467,295      1,841,414        697,934
Income taxes........................................       --             --             --             --
                                                      -------------  -------------  -------------  -------------
NET INCOME..........................................  $     640,328  $     467,295  $   1,841,414  $     697,934
                                                      -------------  -------------  -------------  -------------
                                                      -------------  -------------  -------------  -------------
NET INCOME PER SHARE................................  $         .06  $         .05  $         .17  $         .08
                                                      -------------  -------------  -------------  -------------
                                                      -------------  -------------  -------------  -------------
SHARES USED IN COMPUTING NET INCOME PER SHARE.......     11,076,759      9,427,284     11,108,336      8,516,658
                                                      -------------  -------------  -------------  -------------
                                                      -------------  -------------  -------------  -------------
</TABLE>
 
   The accompanying notes are an integral part of these financial statements.
 
                                       4
<PAGE>
                                  UROCOR, INC.
                            STATEMENTS OF CASH FLOWS
                                  (UNAUDITED)
 
<TABLE>
<CAPTION>
                                                                                      SIX MONTHS ENDED JUNE 30,
                                                                                     ----------------------------
                                                                                         1997           1996
                                                                                     -------------  -------------
<S>                                                                                  <C>            <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
  Net income.......................................................................  $   1,841,414  $     697,934
  Adjustments to reconcile net income to net cash used in operating activities:
    Depreciation and amortization..................................................        685,563        524,312
    Stock option compensation expense..............................................         64,254         65,136
    Loss on disposition of equipment...............................................          1,140       --
    Other..........................................................................       --                 (769)
    Changes in assets and liabilities:
      Increase in accounts receivable..............................................     (4,367,110)    (1,119,181)
      Increase in prepaid expense..................................................       (282,307)      (419,626)
      (Increase) decrease in laboratory supplies...................................        187,290       (314,251)
      Increase in other current assets.............................................       (562,358)      (220,880)
      Increase (decrease) in accounts payable......................................       (869,138)       167,348
      Increase in accrued liabilities..............................................         35,187        122,143
      Decrease in accrued compensation.............................................       (679,652)      (238,017)
                                                                                     -------------  -------------
        Net cash used in operating activities......................................     (3,945,717)      (735,851)
                                                                                     -------------  -------------
CASH FLOWS FROM INVESTING ACTIVITIES:
  Maturities (purchases) of short-term marketable investments, net.................      2,976,586     (3,965,421)
  Purchases of long-term marketable investments, net...............................     (1,001,539)    (4,902,039)
  Capital expenditures.............................................................     (2,810,799)      (951,830)
  Proceeds from capital leases.....................................................       --              385,511
  Intangible and other assets......................................................       (124,232)      (148,297)
                                                                                     -------------  -------------
        Net cash used in investing activities......................................       (959,984)    (9,582,076)
                                                                                     -------------  -------------
CASH FLOWS FROM FINANCING ACTIVITIES:
  Net proceeds from stock issuances................................................       --           34,603,514
  Proceeds from exercise of stock options..........................................         70,425         14,900
  Principal payments under capital lease obligations and other indebtedness........       (318,760)      (433,970)
  Proceeds from line of credit.....................................................       --              600,000
  Payments on line of credit.......................................................       --           (1,300,000)
                                                                                     -------------  -------------
        Net cash provided by (used by) financing activities........................       (248,335)    33,484,444
                                                                                     -------------  -------------
Net increase (decrease) in cash and cash equivalents...............................     (5,154,036)    23,166,517
 
CASH AND CASH EQUIVALENTS, beginning of year.......................................     15,796,070      3,125,296
                                                                                     -------------  -------------
CASH AND CASH EQUIVALENTS, end of period...........................................  $  10,642,034  $  26,291,813
                                                                                     -------------  -------------
                                                                                     -------------  -------------
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
  Cash paid for interest...........................................................  $      85,296  $      96,603
  Cash paid for income taxes.......................................................        350,000         34,000
</TABLE>
 
   The accompanying notes are an integral part of these financial statements.
 
                                       5
<PAGE>
                                  UROCOR, INC.
               NOTES TO INTERIM FINANCIAL STATEMENTS (UNAUDITED)
                                 JUNE 30, 1997
 
NOTE 1--BASIS OF PRESENTATION:
 
    The accompanying unaudited financial statements have been prepared in
accordance with generally accepted accounting principles for interim financial
information and with the instructions to Form 10-Q and Article 10 of Regulation
S-X. Accordingly, they do not include all of the information and footnotes
required by generally accepted accounting principles for complete financial
statements. In the opinion of management, all adjustments (consisting of normal
recurring items) considered necessary for a fair presentation have been
included. These interim financial statements should be read in conjunction with
the financial statements and notes included in the Company's Form 10-K filed on
March 28, 1997.
 
    Operating results for the six-month period ended June 30, 1997 are not
necessarily indicative of the results that may be expected for the full year
ended December 31, 1997.
 
NOTE 2--NET INCOME PER SHARE:
 
    Net income per share has been computed based upon the weighted average
number of common shares and common share equivalents outstanding during each
period. Common share equivalents recognize the potential dilutive effects of the
conversion of Preferred, Class A and Class B Stock to Common Stock for periods
prior to the Company's initial public offering and the impact of outstanding
options and warrants to acquire Common Stock using the treasury stock method and
the Company's estimate of the fair value of common stock during each period.
Pursuant to the rules of the Securities and Exchange Commission, common and
common share equivalent shares issued in the 12 months prior to the Company's
initial public offering, have been included in the computation of common and
common equivalent shares as if they were outstanding for all prior periods
presented.
 
    In February 1997, the Financial Accounting Standards Board issued Statement
of Financial Accounting Standards No. 128, "Earnings per Share" ("SFAS 128").
SFAS 128 requires adoption of certain new accounting and disclosure rules for
earnings per share in financial statements dated after December 15, 1997, and
early adoption is prohibited. Upon adoption, SFAS 128 will require that all
prior-period earnings per share ("EPS") data presented be restated to conform
with the new requirements. The shares used to calculate net income per share, as
presented in these financial statements, will approximate the shares to be used
for Diluted EPS under SFAS 128. To calculate Basic EPS under SFAS 128, the
shares used in computing net income per share for the periods presented in these
financial statements will be reduced by approximately 916,000 and 1,156,000
shares for each of the three month periods ended June 30, 1997 and 1996,
respectively and 958,000 and 1,104,000 for each of the six month periods ended
June 30, 1997 and 1996, respectively.
 
NOTE 3--INITIAL PUBLIC OFFERING:
 
    The Company's initial public offering was consummated on May 22, 1996,
pursuant to which the Company sold a total of 3,450,000 common shares at an
offering price to the public of $11 per share. The net proceeds to the Company
were approximately $34,500,000 after deducting expenses and underwriting
discount.
 
NOTE 4--INVESTMENTS:
 
    Pursuant to the Company's investment policy, idle and excess funds are
invested in high grade, fixed income securities generally for no more than two
years. These securities are classified as Available-for-Sale as of June 30,
1997. The Company considers any net unrealized gain or loss on these investments
to be temporary, and reflects such gains or losses as a component of
stockholders' equity. As of June 30, 1997, there was not a material net
unrealized gain or loss on these investments.
 
                                       6
<PAGE>
ITEM 2.    MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
  RESULTS OF OPERATIONS
 
    The Company's expectations with respect to future results of operations that
may be embodied in oral and written forward-looking statements, including any
forward-looking statements that may be contained in this Quarterly Report on
Form 10-Q, are subject to risks and uncertainties that must be considered when
evaluating the likelihood of the Company's realization of such expectations. The
Company's actual results could differ materially. Factors that could cause or
contribute to such differences include, but are not limited to, those discussed
in Item 5 of Part II of this Report.
 
OVERVIEW
 
    UroCor provides a broad range of diagnostic services for the clinical
management of certain urological cancers and diseases. The Company's goal is to
complement its diagnostic services with therapeutic products and information
services in order to become an integrated disease management company serving the
urology market. The Company has established four business groups,
UroDiagnostics, UroSciences, UroTherapeutics and Disease Management Information
Systems, to serve the needs of urologists and managed care organizations for the
diagnostic, prognostic and therapeutic care of patients throughout the entire
course of their diseases.
 
    The Company currently derives substantially all of its revenue from
diagnostic products and services that its UroDiagnostics Group provides to the
urology market to assist in the diagnosis, prognosis and management of prostate
cancer, bladder cancer and kidney stones disease. The Company recognizes revenue
when products are sold or services are rendered. The Company typically bills
various third-party payors for its products and services, including governmental
programs such as Medicare, private insurance and managed care plans, as well as
individual patients. For the six months ended June 30, 1997, approximately 48%,
38%, 10% and 4% of the Company's revenue was attributable to Medicare, private
insurance and managed care, individual patients, and physicians and hospitals,
respectively.
 
RESULTS OF OPERATIONS
 
    REVENUE.  Revenue increased 20.9%, from approximately $6.4 million in the
three months ended June 30, 1996 to approximately $7.8 million in the three
months ended June 30, 1997, and increased 28.5%, from approximately $12.4
million in the first six months of 1996 to approximately $15.9 million in the
first six months of 1997. These increases resulted from an increase in case
volume of 30.5% and 45.9% for the three and six month periods, respectively, due
primarily to expansion of the Company's client base, increased utilization of
the Company's diagnostic products and services by existing clients and increased
utilization of the Company's kidney stone product line. Case volume increased at
a higher rate than revenue primarily due to the continued expansion of the
kidney stone product line, introduced in early 1996, and an increase in serum
based tests, each of which generally has average selling prices below those of
most of the Company's other products.
 
    DIRECT COST OF SERVICES AND PRODUCTS.  Direct cost of services and products
increased 22.3%, from approximately $2.4 million in the three months ended June
30, 1996 to approximately $2.9 million in the three months ended June 30, 1997,
and increased 30.4%, from approximately $4.5 million in the first six months of
1996 to approximately $5.9 million in the first six months of 1997. These
increases were due principally to higher personnel costs and supply and
distribution costs resulting from increased case volume. As a percentage of
revenue, direct expenses increased to 37.5% for the three months ended June 30,
1997 from 37.1% for the three months ended June 30, 1996, and increased to 37.2%
of revenue for the first six months of 1997 from 36.6% for the first six months
of 1996. These increases are due principally to continued growth of the
Company's kidney stone and serum based tests, with each of these products having
lower profit margins than those of most of the Company's other products.
 
    SELLING, GENERAL AND ADMINISTRATIVE EXPENSES.  Selling, general and
administrative expenses increased 28.6%, from approximately $3.1 million in the
three months ended June 30, 1996 to approximately $4.0
 
                                       7
<PAGE>
million in the three months ended June 30, 1997, and increased 28.7%, from
approximately $6.0 million in the first six months of 1996 to approximately $7.7
million in the first six months of 1997. These increases were due principally to
higher personnel costs related to marketing, sales staff and management
information services personnel, increased provision for doubtful accounts due to
higher revenues, and expanded investor relations activities. As a percentage of
revenue, selling, general and administrative expenses increased to 51.2% for the
three months ended June 30, 1997 from 48.1% for the three months ended June 30,
1996, and increased to 48.4% of revenue for the first six months of 1997 from
48.3% for the first six months of 1996.
 
    RESEARCH AND DEVELOPMENT EXPENSES.  Research and development costs decreased
5.7%, from approximately $649,000 in the three months ended June 30, 1996 to
approximately $611,000 in the three months ended June 30, 1997, and decreased
5.5% , from approximately $1.3 million in the first six months of 1996 to
approximately $1.2 million in the first six months of 1997. As a percentage of
revenue, research and development expenses decreased to 7.8% for the three
months ended June 30, 1997 from 10.1% for the three months ended June 30, 1996,
and decreased to 7.7% of revenue for the first six months of 1997 from 10.5% for
the first six months of 1996.
 
    OTHER INCOME (EXPENSE).  Interest income increased in the three-month period
ended June 30, 1997 compared to the same period of 1996, due principally to the
increased cash, cash equivalents and investments that resulted from the proceeds
of the Company's initial public offering in May 1996. Interest expense decreased
in the three and six month periods ended June 30, 1997 compared to the same
periods of 1996, primarily because the Company did not renew a bank credit
facility upon its expiration in February 1997. The Company had no borrowings
under this facility during the three and six month periods ended June 30, 1997,
and did have borrowings thereunder during the comparable periods in 1996.
 
LIQUIDITY AND CAPITAL RESOURCES
 
    As of June 30, 1997, the Company had cash and cash equivalents of
approximately $10.6 million, short-term marketable investments of approximately
$3.0 million and long-term marketable investments of approximately $12.7
million. Such marketable investments consisted principally of high-grade fixed
income securities, with a maturity of less than two years. As of June 30, 1997
the Company's working capital was approximately $26.4 million.
 
    Accounts receivable, net of allowance for doubtful accounts, totaled
approximately $12.6 million at June 30, 1997, an increase of 53% from December
31, 1996. At June 30, 1997, the Company's average number of days sales in
receivables was approximately 146 compared to 117 and 97 at March 31, 1997 and
December 31, 1996, respectively. During 1996 and 1997, the Company's Medicare
intermediary and certain other third-party payors have continued a general trend
of increased time between their receipt of claims and payment to the Company.
The increase in accounts receivable during the second quarter of 1997 was due
primarily to payor delays caused by systems changes enacted by two of the
Company's larger payors during the quarter. The Company is working closely with
these two payors to resolve systems and related processing issues. In an effort
to reduce its average number of days sales in receivables, the Company has
implemented staffing, systems and process changes and is undertaking additional
initiatives intended to improve its claims and collections efficiencies.
 
    The Company monitors the collection quality of its accounts receivable
through analytical review of aging categories by payor group and collections
performance compared to historical trends. The Company maintains what it
believes to be an adequate level of an allowance for doubtful accounts through
charges to operations which are included in selling, general and administrative
expenses. The Company historically has not experienced any material write-off or
collection problems for which adequate reserves had not been established through
its regular provision for doubtful accounts.
 
    Operating activities used net cash of approximately $3.9 million for the six
months ended June 30, 1997 compared to approximately $736,000 for the six months
ended June 30, 1996. The net cash used in
 
                                       8
<PAGE>
operating activities was primarily the result of an approximate $4.4 million
increase in accounts receivable, an approximate $869,000 decrease in accounts
payable, an approximate $680,000 decrease in accrued compensation, and an
approximate $562,000 increase in other current assets offset in part by net
income of approximately $1.8 million and depreciation and amortization of
approximately $686,000.
 
    Net cash used by investing activities was approximately $960,000 for the six
months ended June 30, 1997 and consisted primarily of capital expenditures of
approximately $2.8 million and purchases of long-term investments of
approximately $1.0 million, offset by net sales of short-term investments of
approximately $3.0 million. Net cash used in financing activities was
approximately $248,000 for the first six months of 1997, consisting primarily of
principal payments under capital leases and other indebtedness of approximately
$319,000 offset by proceeds from exercise of stock options of approximately
$70,000.
 
    The Company's capital expenditures of approximately $2.8 million for the six
months ended June 30, 1997, were primarily for computer hardware and software,
furniture and fixtures and software development for the Company's information
services. Of the total amount, approximately $496,000 related to internal
software development costs for information services. While future capital
expenditures will depend upon a number of factors, the level of expenditures is
expected to be higher than the historical level of such expenditures as the
Company expands to deliver therapeutics and information services and continues
to enhance current diagnostic services and operational capabilities. The Company
intends to finance the majority of these capital expenditures with existing cash
and investment balances.
 
    In December 1994, the Company obtained distribution rights to a therapeutic
product currently under review for marketing approval by the United States Food
and Drug Administration (the "FDA"). The total cost of the distribution rights
is $3.0 million, which is payable in installments based on achievement of
certain milestones by the manufacturer. The Company made an initial payment of
$750,000 in December 1994 and a second installment of $500,000 in 1995 after the
product was submitted for FDA review in April 1995. The Company is obligated to
pay an additional milestone payment of $1.75 million if and when the product is
approved by the FDA for marketing in the United States. If the Company makes
this payment in 1998, it intends to make any such payment from existing cash and
investment balances.
 
    The Company reported no tax expense for the three and six month periods
ended June 30, 1997, as a result of utilization of net operating loss
carryforwards. Prior to 1997, a valuation allowance against the future benefits
of these net deferred tax assets was recorded due to uncertainty regarding the
realizability of such assets through sustained profitable operations. As
realizability of this asset becomes more certain through a demonstrated positive
earnings history, the Company will continue to evaluate the appropriateness of
recognizing these future benefits to a greater extent later in 1997. Using an
assumed tax rate of 38%, the recognition of such net deferred tax benefits
totaled approximately $243,000 or $0.02 per share, for the second quarter of
1997 and $700,000 or $0.06 per share, for the six months ended June 30, 1997.
 
    The Company believes that its existing capital resources will be sufficient
to provide the funds necessary to maintain its present level of operations and
implement its currently planned growth strategy. However, there may be
circumstances or new business opportunities that would require additional
resources. In such event, the Company may be required to seek additional
financing and there is no assurance that the Company would be able to obtain
such financing on acceptable terms.
 
ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
 
    Not Applicable.
 
                                       9
<PAGE>
                           PART II--OTHER INFORMATION
 
ITEM 1.  LEGAL PROCEEDINGS
 
    None
 
ITEM 2.  CHANGES IN SECURITIES
 
    None
 
ITEM 3.  DEFAULTS UPON SENIOR SECURITIES
 
    None
 
ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
 
    On June 20, 1997, at the Company's annual meeting of stockholders:
 
        A) The individuals listed below were elected to serve as Class I
    directors until the 2000 annual meeting. Set forth is the tabulation of
    votes cast. No votes were cast against any nominee for director.
 
<TABLE>
<CAPTION>
         NAME           SHARES VOTED FOR   SHARES WITHHELD      BROKER NON-VOTES
----------------------  ----------------  -----------------  -----------------------
<S>                     <C>               <C>                <C>
Herbert J. Conrad            9,117,228            4,200                     0
Louis M. Sherwood            9,117,028            4,400                     0
</TABLE>
 
        B) The stockholders approved the UroCor, Inc. Second Amended and
    Restated 1992 Stock Option Plan to increase the number shares for which
    options may be granted under such Plan from 1,400,000 to 1,700,000 and amend
    certain provisions of the plan to bring the plan into compliance with
    recently amended federal securities and tax laws. The tabulation of votes
    with respect to this item is as follows:
 
<TABLE>
<CAPTION>
                         SHARES VOTED
  SHARES VOTED FOR          AGAINST        SHARES ABSTAINED      BROKER NON-VOTES
--------------------  -------------------  -----------------  -----------------------
<S>                   <C>                  <C>                <C>
     8,783,425               291,107              46,896                     0
</TABLE>
 
        C) The stockholders approved the UroCor, Inc. 1997 Non-Employee Director
    Stock Option Plan. The tabulation of votes with respect to this item is as
    follows:
 
<TABLE>
<CAPTION>
                         SHARES VOTED
  SHARES VOTED FOR          AGAINST        SHARES ABSTAINED      BROKER NON-VOTES
--------------------  -------------------  -----------------  -----------------------
<S>                   <C>                  <C>                <C>
     9,026,821                38,611              55,996                     0
</TABLE>
 
ITEM 5.  OTHER INFORMATION
 
    Cautionary Statements:
 
        The Company's expectations with respect to future results of operations
    that may be embodied in oral and written forward-looking statements,
    including any forward-looking statements that may be contained in this
    Quarterly Report on Form 10-Q, are subject to risks and uncertainties that
    must be considered when evaluating the likelihood of the Company's
    realization of such expectations. The Company's actual results could differ
    materially. Factors that could cause or contribute to such differences
    include, but are not limited to, those discussed below.
 
        NEED FOR FUTURE FUNDING; UNCERTAINTY OF ACCESS TO CAPITAL.  The
    Company's growth since 1991 has required, and any future growth will
    require, significant amounts of working capital. Although the Company
    believes that existing capital resources will be adequate to fund its
    present level of operations and implement its currently planned growth
    strategy, there may be circumstances or new business opportunities that
    would require additional resources. In such event, the Company may be
 
                                       10
<PAGE>
    required to seek additional financing, and there is no assurance that the
    Company would be able to obtain such financing on acceptable terms.
 
        UNCERTAINTIES RELATED TO THIRD-PARTY REIMBURSEMENT; POTENTIAL HEALTH
    CARE REFORM.  The Company typically bills governmental programs such as
    Medicare and other third-party payors such as private insurance and managed
    care plans for its products and services. Such third-party payors are
    increasingly negotiating prices with the goal of lowering reimbursement
    rates, which may result in lower profit margins for the Company.
    Reimbursement rates have been established for most but not all of the
    services performed by the Company. The Company cannot collect from Medicare
    or other third-party payors for services that those payors have not approved
    for reimbursement. There can be no assurance that the Company's Free/Total
    PSA product or any other products under development will be approved for
    reimbursement by Medicare or other third-party payors. From time to time,
    the public and federal government focus significant attention on reforming
    the health care system in the United States. Any future changes in Medicare
    and other third-party payor reimbursement which may result from health care
    reform or deficit reduction legislation will likely continue the downward
    pressure on prices. A number of legislative proposals have been introduced
    in Congress and state legislatures in recent years that would effect major
    reforms of the health care system and otherwise reduce health care spending.
    The Clinton Administration's recently proposed fiscal year 1998 federal
    budget contains many provisions, which if enacted, will substantively affect
    Medicare reimbursement. Because of the uncertainties surrounding the nature,
    timing and extent of any such reform initiatives, the Company is unable to
    predict the effects of any such changes on the Company.
 
        DEPENDENCE ON CERTAIN PRODUCT LINES.  A significant portion of the
    Company's revenue has been, and is expected to continue to be, dependent
    upon the Company's prostate tissue analysis and bladder cellular analysis
    product lines. Any negative event related to these product lines, such as
    increased competition, pricing pressures and clinical or technological
    obsolescence would have a material and adverse effect on the Company's
    financial condition and results of operations.
 
        NO ASSURANCE OF SUCCESSFUL ACQUISITION OF DISTRIBUTION RIGHTS FOR
    THERAPEUTIC PRODUCTS.  Through its UroTherapeutics Group, the Company is
    developing a therapeutic products distribution business. The Company
    currently has acquired distribution rights for only one therapeutic product.
    There can be no assurance that the Company will be successful in negotiating
    any additional distribution or other agreements related to therapeutic
    products in the future. Additionally, the Company has never marketed or
    distributed any therapeutic products, and there can be no assurance that the
    Company's efforts will be successful.
 
        UNCERTAINTY RELATED TO GOVERNMENT REGULATION.  The Company's diagnostic
    laboratory operations currently are required to be certified or licensed
    under the federal Clinical Laboratory Improvement Act of 1967, as amended in
    1988 ("CLIA"), the Medicare and Medicaid programs and various state and
    local laws. In some instances, the Company is also subject to licensing or
    regulation under federal and state laws relating to the handling and
    disposal of medical specimens, infectious and hazardous waste and
    radioactive materials, as well as to the safety and health of laboratory
    employees. The sanctions for failure to comply with these regulations may
    include denial of the right to conduct business, significant fines and
    criminal penalties. The loss of a license, imposition of a fine or an
    increase in the complexity or substantive requirements of such federal,
    state and local laws and regulations could have a material adverse effect on
    the Company's financial condition and results of operations.
 
        The Company's diagnostic laboratory operations currently are not
    regulated by the FDA. While the FDA now indicates that it does not plan to
    regulate assays developed by laboratories for in-house use, the FDA has in
    the past considered drafting guidelines for regulation of such assays. If in
    the future the FDA were to issue guidelines for the clinical laboratory
    market sector, such guidelines might require the Company to meet certain FDA
    medical device approval requirements for the
 
                                       11
<PAGE>
    Company's in-house assays. Such regulations, if enacted in a way that
    affects the Company, would increase the cost of development and approval of
    new products, slow their introduction to the market and could have a
    material adverse effect on the Company's financial condition and results of
    operations.
 
        The FDA currently regulates a number of the products which the Company
    purchases from third parties for use in its diagnostic services. The
    manufacturers of such products are responsible for compliance with FDA
    regulations relating to such products. There can be no assurance, however,
    that action by the manufacturers or by the FDA would not impair the
    Company's ability to obtain and offer certain services. The unavailability
    of certain services and materials used in the Company's diagnostics business
    would have a material adverse effect on the Company's financial condition
    and results of operations.
 
        Although the Company's existing and proposed information services
    products currently are not subject to regulation by the FDA, the FDA could
    determine in the future that the predictive applications of these products
    are deemed to be medical devices subject to FDA regulation. In that event,
    the Company could experience delays in developing and marketing new services
    and increases in research and development costs.
 
        As a provider of health care related services, the Company is subject to
    extensive and frequently changing federal, state and local laws and
    regulations governing licensure, billing, financial relationships,
    referrals, conduct of operations, purchase of existing businesses,
    cost-containment, direct employment of licensed professionals by business
    corporations and other aspects of the Company's business relationships. The
    Company cannot predict the timing or impact of any changes in such laws and
    regulations or their interpretations by regulatory bodies, and no assurance
    can be given that any such changes will not have a material adverse effect
    on the Company's financial condition and results of operations.
 
        UNCERTAINTIES RELATED TO THE FDA APPROVAL OF THERAPEUTIC PRODUCT.  The
    Company has a distribution agreement with IAF BioVac, Inc. ("BioVac"), for a
    therapeutic product for use in treating certain types of bladder cancer.
    Pursuant to the distribution agreement, BioVac is responsible for obtaining
    approvals from the FDA for marketing the therapeutic product in the United
    States. In April 1995, BioVac filed its initial applications with the FDA.
    In April 1996, the FDA advised BioVac that its application was not
    approvable and requested additional data regarding certain aspects of
    manufacturing and testing of the product, which BioVac filed with the FDA
    through an amended application in August 1996. Following a May 1997 site
    inspection of BioVac's manufacturing facilities and operations, the FDA
    issued a report on FDA Form 483 indicating that additional requirements
    related to BioVac's facility, process and documentation were required before
    these applications could be approved. Although BioVac has advised the
    Company that it believes it can satisfy the FDA requirements, there can be
    no assurance that approval will be obtained.
 
        UNCERTAINTIES RELATED TO MANAGED CARE.  Managed care organizations are
    gaining increasing control over access to health care and payment for an
    increasing number of patients with urological diseases. There can be no
    assurance that the Company will be able to maintain its existing contracts
    with managed care organizations or that it will be able to obtain additional
    contracts with such organizations in the future which could preclude the
    Company from serving large groups of patients in certain markets. The
    Company has experienced increasing pricing pressure from managed care
    organizations, and such pressure is expected to continue. There can be no
    assurance that such pricing pressure and any contract restrictions will not
    have a material adverse effect on the Company's financial condition and
    results of operations.
 
        NO ASSURANCE OF ACCESS TO AND DELIVERY OF NEW DIAGNOSTIC
    TECHNOLOGY.  The markets for the Company's diagnostic products and services
    are characterized by rapidly changing technology, frequent new product
    introductions and enhancement and, therefore, rapid product obsolescence.
    There can be no
 
                                       12
<PAGE>
    assurance the Company will be able to identify new products, trends or
    opportunities, develop and bring to market new products, respond effectively
    to new technological changes or product announcements by others, develop or
    obtain access to advanced materials and technologies, or receive commercial
    acceptance for its products.
 
        UNCERTAINTIES RELATED TO INVESTMENTS IN DISEASE MANAGEMENT INFORMATION
    SYSTEMS.  The Company has been and expects to continue investing in the
    development of information-based capabilities and services which it plans to
    introduce in the future related to the clinical management of urologists'
    patients and the business management of their practices. Development and
    delivery of these new services will require substantial additional
    investment and represents an expansion of the type of services the Company
    presently provides to urologists. There can be no assurance that any future
    revenues from these services will be sufficient to cover or otherwise
    justify the costs of development and introduction.
 
        UNCERTAINTIES ASSOCIATED WITH COMPETITIVE PRESSURES.  The industry in
    which the Company's diagnostics business operates is characterized by
    intense competition with many different types of competitors including
    specialty laboratories, diagnostic kit and instrumentation manufacturers,
    local and regional pathology services, hospital laboratories and large
    general reference clinical laboratories. Many of the Company's competitors
    are significantly larger and have significantly greater financial, technical
    and administrative resources than the Company; many also have long
    established relationships with the Company's current and prospective
    customers and with managed care organizations. There can be no assurance
    that the Company will be able to compete successfully with such entities in
    the marketing of products and services and in the acquisition of new
    technologies.
 
        RISKS ASSOCIATED WITH MANAGEMENT OF GROWTH.  The Company has recently
    experienced substantial growth and expanded its operational capabilities.
    The Company is also planning to offer a therapeutic product line and
    information and business management services. This growth and expansion has
    placed, and will continue to place, a significant strain on the Company's
    management, production, technical, financial and other resources. To date,
    the Company primarily has experience in managing a diagnostics service
    business. There can be no assurance that the Company will be able to manage
    expansion into and operation of therapeutics, business management or
    information services businesses.
 
        POTENTIAL FLUCTUATIONS IN OPERATING RESULTS.  The Company's quarterly
    and annual operating results are affected by a wide variety of factors, many
    of which are outside the Company's control, which have in the past and could
    in the future materially and adversely affect revenue, operating expenses
    and income. These factors include seasonality, the quantities and timing of
    specimens received, competitive pricing pressures, availability and cost of
    diagnostic supplies, changes in the mix of products sold, timing and costs
    of new product and technology introductions by the Company or its
    competitors, retention and expansion of the sales force and timing of
    payments from Medicare and other third-party payors. The need for continued
    investment in research and development and expansion of its product lines
    could limit the Company's ability to reduce expenses quickly. As a result of
    these factors, the Company expects its operating results to continue to
    fluctuate.
 
ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K.
 
    (a) Exhibits
 
<TABLE>
<CAPTION>
EXHIBIT NUMBER AND DESCRIPTION
---------------------------------------------------------------------------------
<C>    <S>
 10.1  Second Amended and Restated 1992 Stock Option Plan
 10.2  1997 Non-Employee Director Stock Option Plan
 10.3  Amendment No. 1 to Lease Agreement dated April 15, 1994, between
         Presbyterian Health Foundation and UroCor, Inc.
 11.1  Statement Regarding Computation of Per Share Earnings
</TABLE>
 
    (b) Reports on Form 8-K
 
        None
 
                                       13
<PAGE>
                                   SIGNATURES
 
    Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
 
<TABLE>
<S>                             <C>  <C>
                                UROCOR, INC.
 
                                By:           /s/ WILLIAM A. HAGSTROM
                                     -----------------------------------------
                                                William A. Hagstrom
                                     CHAIRMAN OF THE BOARD, PRESIDENT AND CHIEF
                                                 EXECUTIVE OFFICER
August 11, 1997
 
                                By:           /s/ MICHAEL N. MCDONALD
                                     -----------------------------------------
                                                Michael N. McDonald
                                     VICE-PRESIDENT AND CHIEF FINANCIAL OFFICER
August 11, 1997
</TABLE>
 
                                       14